| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/08/2001 | WO2001009173A2 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | WO2001009172A2 Immunogenic polypeptide derived from moraxella catarrhalis and uses thereof |
| 02/08/2001 | WO2001008707A2 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes |
| 02/08/2001 | WO2001008703A1 Recombinant rsv virus expression systems and vaccines |
| 02/08/2001 | WO2001008702A2 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 02/08/2001 | WO2001008701A2 Invasive bacteria based viral vaccines |
| 02/08/2001 | WO2001008636A2 Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein |
| 02/08/2001 | WO2001008634A2 Polynucleotide encoding a human serine protease |
| 02/08/2001 | WO2001008495A1 Rotavirus vaccine formulations |
| 02/08/2001 | WO2001008486A1 CoaA POLYPEPTIDES AND POLYNUCLEOTIDES AND METHODS THEREOF |
| 02/08/2001 | WO2000076540A3 Streptococcus pneumoniae proteins and vaccines |
| 02/08/2001 | WO2000075317A3 Compositions and methods for the treatment of tumor |
| 02/08/2001 | WO2000069456A3 Adjuvant combination formulations |
| 02/08/2001 | WO2000068261A3 Attenuated microorganisms for the treatment of infection |
| 02/08/2001 | WO2000067785A3 Staphyloccocus aureus antigen-containing whole cell vaccine |
| 02/08/2001 | WO2000067700A3 Recombinant vaccine against botulinum neurotoxin |
| 02/08/2001 | WO2000066710A3 Method for the preservation of viruses and mycoplasma |
| 02/08/2001 | WO2000066141A3 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/08/2001 | WO2000064464A8 NUCLEIC ACIDS AND PROTEINS OF A RAT GANGLIOSIDE GM1-SPECIFIC αl→2FUCOSYLTRANSFERASE AND USES THEREOF |
| 02/08/2001 | WO2000063350A3 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis |
| 02/08/2001 | WO2000063230A3 49 human secreted proteins |
| 02/08/2001 | WO2000062816A3 Genetic tolerization |
| 02/08/2001 | WO2000062815A3 Novel pharmaceutical composition suitable for gene therapy |
| 02/08/2001 | WO2000061772A3 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| 02/08/2001 | WO2000061756A3 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| 02/08/2001 | WO2000061183A3 Verotoxin treatment of lymphomas |
| 02/08/2001 | WO2000059525A3 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 02/08/2001 | WO2000057919A3 Lipid-based artificial particles inducing cell-mediated immunity |
| 02/08/2001 | WO2000050455A3 Antigen to systemic lupus erythematosis and diagnostic assay |
| 02/08/2001 | WO2000020864A8 Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors |
| 02/08/2001 | DE19936563A1 Tumorassoziiertes Antigen Tumor-associated antigen |
| 02/08/2001 | DE19935302A1 Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen Conjugates and methods for their preparation and their use for transporting molecules across biological membranes |
| 02/08/2001 | CA2820314A1 Vaccine composition |
| 02/08/2001 | CA2820271A1 Vaccine composition |
| 02/08/2001 | CA2388663A1 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands |
| 02/08/2001 | CA2381945A1 Mammalian adhesion protease peptides |
| 02/08/2001 | CA2381056A1 Recombinant hsv-1 and live viral vaccines |
| 02/08/2001 | CA2380840A1 Vaccine composition |
| 02/08/2001 | CA2380831A1 Moraxella catarrhalis antigen basb117 |
| 02/08/2001 | CA2380825A1 Basb116 dna and proteins from moraxella catarrhalis |
| 02/08/2001 | CA2380822A1 Basb119 polypeptide and polynucleotide from moraxella catarrhalis |
| 02/08/2001 | CA2380819A1 Basb120 polypeptide and polynucleotide from moraxella catarrhalis |
| 02/08/2001 | CA2380813A1 Human monoclonal antibodies to her2/neu |
| 02/08/2001 | CA2380803A1 Basb118 polypeptide and polynucleotide from moraxella catarrhalis |
| 02/08/2001 | CA2380799A1 Rescue of mumps virus from cdna |
| 02/08/2001 | CA2380518A1 Novel compounds |
| 02/08/2001 | CA2380515A1 Polypeptides and polynucleotides from moraxella catarrhalis |
| 02/08/2001 | CA2380514A1 Attenuated influenza virus useful as vaccine |
| 02/08/2001 | CA2380506A1 Novel compounds |
| 02/08/2001 | CA2380501A1 Novel compounds |
| 02/08/2001 | CA2380498A1 Novel compounds |
| 02/08/2001 | CA2380407A1 Method for in vitro culture of viruses of the togaviridae and flaviviridae family and uses |
| 02/08/2001 | CA2380351A1 Basb126 polypeptide and polynucleotide from moraxella catarrhalis |
| 02/08/2001 | CA2380295A1 Moraxella cattarrhalis basb114 antigens and uses thereof |
| 02/08/2001 | CA2380108A1 Recombinant rsv virus expression systems and vaccines |
| 02/08/2001 | CA2380018A1 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 02/08/2001 | CA2379832A1 Invasive bacteria-based viral vaccines |
| 02/08/2001 | CA2378929A1 Serine proteases |
| 02/08/2001 | CA2378864A1 Rotavirus vaccine formulations |
| 02/08/2001 | CA2378182A1 Compositions and methods for the treatment of tumors |
| 02/08/2001 | CA2378168A1 Moraxella catarrhalis antigens basb122 and basb124 |
| 02/07/2001 | EP1074842A1 Catalytic anti-factor VIII allo-antibodies |
| 02/07/2001 | EP1074634A1 Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease |
| 02/07/2001 | EP1074627A2 25-hydroxyvitamin D3-1a-hydroxylase and DNA encoding the hydroxylase |
| 02/07/2001 | EP1074625A2 DNA vaccine against feline immunodeficiency virus |
| 02/07/2001 | EP1074618A2 Cadherin materials and methods |
| 02/07/2001 | EP1074614A1 A recombinant Newcastle disease virus for in ovo vaccination |
| 02/07/2001 | EP1074612A1 Use of vegetal peptones for DNA vaccine production |
| 02/07/2001 | EP1074563A1 Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| 02/07/2001 | EP1074268A1 Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient il-6 antagonists |
| 02/07/2001 | EP1074267A1 Induction of antigen-specific T cells by interferon |
| 02/07/2001 | EP1074266A2 Live attenuated bacteria for use in a vaccine |
| 02/07/2001 | EP1073905A1 Methods of selecting internalizing antibodies |
| 02/07/2001 | EP1073760A1 Adenovirus mutants with deleted protease gene, complementing cell lines and corresponding vectors for gene transfer |
| 02/07/2001 | EP1073759A1 Recombinant virus expressing foreign dna encoding feline cd80, feline cd28, feline ctla-4 or feline cd86 and uses thereof |
| 02/07/2001 | EP1073751A2 Polypeptide with immunogenic properties and with a protein with modified biological functions |
| 02/07/2001 | EP1073750A1 Preparation of human papillomavirus e1 having helicase activity and method therefor |
| 02/07/2001 | EP1073749A2 Enhancing immune responses to genetic immunization by using a chemokine |
| 02/07/2001 | EP1073748A2 Vaccines containing recombinant pilin against neisseria gonorrhoeae or neisseria meningitidis |
| 02/07/2001 | EP1073747A1 Basb013 dna and proteins from neisseria meningitidis |
| 02/07/2001 | EP1073745A2 Immunization against and treatment for infection by h. pylori |
| 02/07/2001 | EP1073742A2 Human nucleic acid sequences of bladder tumour tissue |
| 02/07/2001 | EP1073741A2 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides |
| 02/07/2001 | EP1073737A2 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 02/07/2001 | EP1073735A1 Host-encoded protein expressed on marek's disease virus (mdv)-infected cells and antibody thereto |
| 02/07/2001 | EP1073734A2 Tumor associated nucleic acids and uses therefor |
| 02/07/2001 | EP1073733A1 MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY |
| 02/07/2001 | EP1073710A2 Non-stochastic generation of genetic vaccines and enzymes |
| 02/07/2001 | EP1073683A1 G-csf receptor agonist antibodies and screening method therefor |
| 02/07/2001 | EP1073682A1 Heparanase specific molecular probes and their use in research and medical applications |
| 02/07/2001 | EP1073667A2 Polysaccharide-antigen conjugates |
| 02/07/2001 | EP1073465A1 T cell inhibitory receptor compositions and uses thereof |
| 02/07/2001 | EP1073464A1 Monoclonal antibodies with reduced immunogenicity |
| 02/07/2001 | EP1073462A2 Hepatitis vaccine |
| 02/07/2001 | EP1073461A1 Viral chimeras comprised of caev and hiv-1 genetic elements |
| 02/07/2001 | EP1073460A1 Nucleic acid encoding hyaluronan synthase and methods of use |
| 02/07/2001 | EP1073459A1 Compositions and methods for tolerization in immune complex-mediated disease progression |
| 02/07/2001 | EP1073458A1 Chlamydia proteins and their uses |
| 02/07/2001 | EP1073457A1 Modifications of antigens by the introduction of aldehyde groups and their use in enhancing the immune response |
| 02/07/2001 | EP1073455A1 Compositions and methods for extending the action of clostridial neurotoxin |